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Abstract
Cluster headache (CH) is a primary headache disease characterized by recurrent short-lasting
attacks (15 to 180 minutes) of excruciating unilateral periorbital pain accompanied by ipsilateral
autonomic signs (lacrimation, nasal congestion, ptosis, miosis, lid edema, redness of the eye). It
affects young adults, predominantly males. Prevalence is estimated at 0.5–1.0/1,000. CH has a
circannual and circadian periodicity, attacks being clustered (hence the name) in bouts that can
occur during specific months of the year. Alcohol is the only dietary trigger of CH, strong odors
(mainly solvents and cigarette smoke) and napping may also trigger CH attacks. During bouts,
attacks may happen at precise hours, especially during the night. During the attacks, patients tend
to be restless. CH may be episodic or chronic, depending on the presence of remission periods.
CH is associated with trigeminovascular activation and neuroendocrine and vegetative
disturbances, however, the precise cautive mechanisms remain unknown. Involvement of the
hypothalamus (a structure regulating endocrine function and sleep-wake rhythms) has been
confirmed, explaining, at least in part, the cyclic aspects of CH. The disease is familial in about 10%
of cases. Genetic factors play a role in CH susceptibility, and a causative role has been suggested
for the hypocretin receptor gene. Diagnosis is clinical. Differential diagnoses include other primary
headache diseases such as migraine, paroxysmal hemicrania and SUNCT syndrome. At present,
there is no curative treatment. There are efficient treatments to shorten the painful attacks (acute
treatments) and to reduce the number of daily attacks (prophylactic treatments). Acute treatment
is based on subcutaneous administration of sumatriptan and high-flow oxygen. Verapamil, lithium,
methysergide, prednisone, greater occipital nerve blocks and topiramate may be used for
prophylaxis. In refractory cases, deep-brain stimulation of the hypothalamus and greater occipital
nerve stimulators have been tried in experimental settings. The disease course over a lifetime is
unpredictable. Some patients have only one period of attacks, while in others the disease evolves
from episodic to chronic form.
Disease name and synonyms
Other terms for cluster headache (CH) are erythropro-
sopalgia of Bing, ciliary or migrainous neuralgia, eryth-
romelalgia of the head, Horton's headache, histaminic
cephalalgia, petrosal neuralgia of Gardner, sphenopala-
tine, Vidian and Sluder's neuralgia, and hemicrania peri-
odica neuralgiformis. In French, it is named algie vasculaire
de la face, somewhat a misnomer since CH does not pri-
marily involve a dysfunction of arteries or veins.
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Definition, diagnostic criteria and forms
Cluster headache is a primary headache disease like
migraine or tension-type headache. By contrast to second-
ary headaches, in which the pain is symptomatic of an
underlying brain, cranial or systemic disorder, primary
headaches are due to spontaneous activation of nocicep-
tive pathways. CH is characterized by recurrent attacks of
short-lasting excruciating pain accompanied by signs of
autonomic dysfunction, as described in the second ver-
sion of the International Classification Headaches second
edition (ICHD-II) criteria presented in table 1[1]. The
patient must have had at least five attacks of severe or very
severe unilateral orbital or supraorbital and/or temporal
pain, lasting 15 to 180 minutes if untreated. The headache
is accompanied by one ipsilateral autonomic symptom
among the following: conjunctival injection and lacrima-
tion, nasal congestion or rhinorrhea, forehead and facial
sweating, eyelid edema, miosis and ptosis. In the absence
of autonomic signs, CH can be diagnosed if a sense of rest-
lessness or agitation is present during the attacks.
CH is the most common type of the trigeminal autonomic
cephalalgias (TACs), which include paroxysmal hemicra-
nia and SUNCT (Short Unilateral Neuralgiform headache
with Conjunctival injection and Tearing). It is divided in
episodic (3.1.1) and chronic (3.1.2) forms [1], as detailed
in table 2. In 80% of cases, the disease is episodic and may
present with one or two periods per year, or even may go
into remission for many years before development of
another cluster period. In about 20% of CH patients the
disease is chronic [2]. These patients have ongoing attacks
for one year or more, without more than one month of
remission. These refractory patients are difficult to diag-
nose and manage, and need to be referred to a headache
specialist.
Epidemiology
The prevalence of CH can be estimated at approximately
0,5 – 1.0/1,000 [3-12]. Table 3 summarizes the epidemi-
ological studies on CH. Many of these studies are biased
by the sample chosen and by the difficulties of diagnosing
CH by mailed questionnaires or telephone interviews. In
a tertiary care headache clinic, CH was diagnosed in
2.73% of patients. There is a clear male predominance in
CH, but it has been estimated to be decreasing over the
years [13], maybe due to increased recognition of the dis-
ease in women [14]. CH is a condition affecting young
adults, first attacks usually occurring in the third decade.
It is probably under-diagnosed and unrecognized; a sig-
nificant diagnostic delay has been reported in most
patients [15,16]. CH in children is rare, but a few cases
have been reported [17], the youngest patients being three
years old [18]. Symptoms often decrease after age of 70
years. Heavy smoking has been frequently documented
amongst CH patients [19].
Clinical description: how to recognize cluster 
headache
Duration and frequency of attacks
Cluster headache attacks are unilateral, severe, short-last-
ing (15 to 180 minutes) and recurrent (1 every other day
to 8 per day) [1]. This special pattern is very important to
recognize the cluster headaches and to differentiate them
from migraine attacks. A patient describing a pain lasting
less than three hours, severe and localized on one side of
the head, coming back at specific times of the day or dur-
ing sleep, must be asked if symptoms like tearing, eye
swelling and nasal congestion are present on the other
side. The fact that the attack ends after one or two hours
must not be attributed to a success of standard analgesics,
which are not useful in CH.
Pain description
A prospective study on clinical characteristics of CH has
been published by Bahra et al. [2]. Pain is described
mostly in the first trigeminal branch territory, on one side
of the head only and almost always the same side (rarely,
attacks may switch the location). Pain may be centered on
the eye but may also be periorbital and temporal, some-
times extending to the maxillary, ear or even occipito-cer-
vical region. Some patients describe the pain as radiating
to the teeth, thus they may first consult a dentist. As to its
Table 1: Diagnostic criteria for cluster headache according to the International Classification of Headache Diseases II
3.1 Cluster headache
A. At least five attacks fulfilling B through D
B. Severe or very severe unilateral orbital, supraorbital and/or temporal pain lasting 15 to 180 minutes if untreated
C. Headache is accompanied by at least one of the following:
1. Ipsilateral conjunctival injection and/or lacrimation
2. Ipsilateral nasal congestion and/or rhinorrhea
3. Ipsilateral eyelid edema
4. Ipsilateral forehead and facial sweating
5. Ipsilateral miosis and/or ptosis
6. A sense of restlessness or agitation
D. Attacks have a frequency from one every other day to eight per day
E. Not attributed to another disorderOrphanet Journal of Rare Diseases 2008, 3:20 http://www.ojrd.com/content/3/1/20
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severity, CH is one of the most painful conditions known
to man (worse than giving birth according to female
patients). It is described as excruciating and intolerable.
Patients compare it to a white-hot needle or knife being
pushed into the eye, the eye being crushed or ripped of the
orbit. Suicidal ideations may be expressed during the
attacks. The nickname of the CH among patients is "The
Beast", a term suggesting an animal hiding in the shadow,
attacking in a terrible and unpredictable way. Pain rises
abruptly over a few minutes. It also ends rapidly. In severe
chronic forms or in episodic forms with numerous daily
attacks, there may be a continuous discomfort on the
affected side [20], but usually CH patients are completely
asymptomatic between attacks.
Dysautonomic symptoms
Parasympathetic hyperactivity signs include ipsilateral
lacrimation, redness of the eye and nasal congestion. The
affected side of the face may be red and sweaty. Sympa-
thetic hypoactivity is demonstrated by the combination of
ipsilateral ptosis and miosis (droopy eye and smaller
pupil on the affected side) during attacks. The combina-
tion of ptosis and miosis on one side is called Claude-Ber-
nard-Horner syndrome (CBH). Persistence of CBH signs
after the end of the attack in episodic CH should alert the
clinician to suspect underlying lesion in hypothalamus,
brainstem, paravertebral sympathetic chain or carotid.
Proper investigations should be undertaken: brain mag-
netic resonance imaging (MRI), chest computerized tom-
ography and carotid ultrasound.
Autonomic signs are very prominent in certain patients,
but may be subtle or even absent in 3% of patients [21].
They can be unrecognized because of the pain ("I close my
eye, I cry because I'm in pain"). In case of uncertainty, the
patient can be asked to observe these specific signs during
the attack.
Ictal behavior
Physical activity seems to partially alleviate the pain in
CH. During the attacks, patients tend to be restless. They
may rock from side to side, hit their heads, hit objects with
the fist, or even hit their head against the wall [22]. This
behavior is so typical of CH that it is accepted as an official
criterion in the ICHD-II [1]. Indeed, it is possible to diag-
nose CH without any dysautonomic sign if the behavioral
criterion is satisfied. This restless attitude may help to dif-
ferentiate CH from migraine, where patients are quiet and
avoid any movement. CH patients are cognitively alert,
but may also be irritable and aggressive. There is no men-
tal slowing or fatigue, as it may be seen in migraine
patients.
Cyclicity
CH shows circannual and circadian cyclicity. Peaks have
been described around solstices, in relation to changes in
daylight duration [23]. Attacks can happen at a precise
time during the sleeping cycle, with dramatic regularity
reported by patients. This cyclicity is not observed in all
CH patients and is not included in the ICHD-II criteria,
though most experts find it very suggestive of CH when
present.
Table 2: ICHD-II criteria for episodic and chronic cluster headache
3.1.1 Episodic cluster headache
A. All fulfilling criteria A through E of 3.1
B. At least two cluster periods lasting from 7 to 365 days and separated by pain free remissions of > 1 month.
3.1.2 Chronic cluster headache
A. All fulfilling criteria A through E of 3.1
B. Attacks recur for > 1 year without remission periods or with remission periods lasting < 1 month.
Table 3: Epidemiological studies of cluster headache
Country Diagnosis confirmed Age Sex Population sample Affected Prevalence per 100 000
Sweden [10] Yes 18 Men 9803 9 92
San Marino [3] Yes All Both 21792 14 69
USA [6] No All Both 6476 26 401
San Marino [7] Yes All Both 26628 15 56
Norway [5] Yes 18–65 Both 1838 7 381
Sweden [11] Yes All Both 31750 48 151
Italy [8] Yes 18–65 Both 6500 13 200
Italy [9] Yes Over 14 Both 10071 21 279
Germany [4] Yes 18–65 Both 3336 4 119
Germany [12] Yes 25–75 Both 2291 2 150Orphanet Journal of Rare Diseases 2008, 3:20 http://www.ojrd.com/content/3/1/20
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Triggers
Alcohol is recognized as the only dietary trigger of CH.
Nitroglycerin has been used to trigger attacks for diagnos-
tic purpose (therefore, e nitrates should be avoided during
bouts). Strong odors (mainly solvents and cigarette
smoke) and napping may trigger CH attacks. It is surpris-
ing that all triggers are effective only during bouts. In
between periods, patients may smoke and drink alcohol
without triggering attacks.
Diagnostic delay
There is a significant delay in diagnosing CH (reported
median delay of three years [16]), though there is an
improvement as compared to the 1960's when a diagnos-
tic delay of more than 20 years was not infrequent [15].
Up to 30% of patients have previously undergone many
investigations and seen dentists, ENT (ears, nose, throat)
surgeons, ophthalmologists, even neurologists, without
being diagnosed. Up to 16% may have undergone dental,
sinus or eye surgery [16]. The periodicity of attacks makes
the diagnosis difficult and sometimes suggests an infec-
tious cause. Prednisone can be prescribed for sinusitis and
have a positive effect, falsely confirming an erroneous
diagnosis. Some patients do not seek medical advice once
the bout has ended by itself.
Other features
Though aura is not frequent in CH [24], up to 14% of
patients report aura symptoms, with transient visual,
motor or sensory disturbances preceding the facial pain
[2]. In chronic CH, auras have been reported in 20% of
patients [20]. Nausea, vomiting, photophobia and pho-
nophobia can be observed in approximately 50% of
patients, and must not discard the diagnosis of CH if other
criteria are fulfilled. A shift of the affected side may be
observed within a bout or between two bouts in 15% of
patients [2]. Case reports of "CH sine headache" have
described patients with episodes of unilateral facial auto-
nomic dysfunction without pain [25,26], but this is very
rare.
Etiology: a role for the hypothalamus, but many 
uncertainties
The exact cause of CH is currently unknown. The first
hypotheses on CH, inspired by the effects of vasoactive
substances in CH (dilators causing attacks, constrictors
ending them) were based on the neurovascular theory. An
initial dysfunction or inflammation of the blood vessels
in the parasellar or cavernous sinus area would activate
the orbital trigeminal pain pathways. Indeed, activation of
the trigeminal-vascular system is present, but whether it is
a cause or consequence of CH is not clear. It is not specific
for CH, since it is also very prominent, and much better
demonstrated, in migraine. Later on, the periodicity of CH
has oriented studies toward the hypothalamus, with more
fruitful results. Positron emission tomography (PET)
studies have show an activation of the posterior hypotha-
lamus during CH attacks [27], reinforcing the idea that the
hypothalamus may be the CH generator. Voxel-based
morphometry studies demonstrated an increase in the
gray matter volume of the posterior hypothalamus in CH
patients compared to controls [28]. Success of hypotha-
lamic deep-brain stimulation (DBS) [29] and emerging
evidence for hypocretin receptor gene involvement also
strengthen that hypothesis. Abnormal blood levels of pro-
lactin, testosterone, thyroid stimulating hormone (TSH),
and cortisol may be linked to perturbations in the activity
of the hypothalamic-pituitary-adrenal axis.
Numerous studies have examined blood levels of other
substances in CH patients during attacks, bouts and
remissions. Histamine, prostaglandins, opiates, neu-
ropeptids, amines, nitric oxide, monoamine oxydase,
serotonin and cytokines values may show significant dif-
ferences compared to those in non-affected controls. The
list is long but, so far, none of these studies allowed a
coherent understanding of CH. The parasympathetic acti-
vation is thought to be mediated by the trigeminal-auto-
nomic reflex in the brainstem circuitry,via  the seventh
cranial nerve. The sympathetic innervation pathway to the
pupil and eyelid is composed of three neurons and there
is no clear demonstration of the site involved and mecha-
nisms underlying the dysfunction in CH. The reason for
the male predominance of CH also remains to be clari-
fied.
Genetics
Initially, CH was not thought to be a genetic disease. With
official criteria published and the increasing recognition
of the disease, a genetic aspect of CH has been identified.
Cases of twin pairs affected by CH have been published
[30-32]. Studies using large twin registries have shown
that monozygotic twins present a higher concordance rate
for CH (2/12 pairs) than dizygotic twins (0/25 pairs),
indicating the existence of genetic factors, but monozy-
gotic twins can also be concordant or discordant for CH,
confirming a role for environmental factors [11,33]. Fam-
ily studies of CH patients' cohorts have shown a familial
aggregation in 7% to 20% of patients, and a relative risk
for first-degree relatives between 14 and 39 [34-36]. The
transmission mode has still not been established. Some
studies have suggested an autosomal dominant way with
incomplete penetrance [37], while other described an
autosomal recessive transmission [38]. So far, no X-linked
pedigrees have been published. No susceptibility locus
has been identified. Much work has recently been done on
the HCRTR2 gene (hypocretin receptor 2) polymorphism
[39,40], suggesting a role of this gene in CH susceptibility.
Hypocretins are secreted in the hypothalamus, a structure
clearly involved in CH. All these findings suggest thatOrphanet Journal of Rare Diseases 2008, 3:20 http://www.ojrd.com/content/3/1/20
Page 5 of 11
(page number not for citation purposes)
genetic factors do play a role in CH [41,42], though, so far,
the transmission mode remains to be established and the
contribution of individual factors to be clearly under-
stood. The HCRTR2 gene is a promising research area.
Diagnostic methods
Diagnosis of cluster headache is based on clinical criteria
and exclusion of a secondary cause. A first attack sugges-
tive of CH must always be thoroughly investigated, and
carotid dissection has to be properly excluded either with
doppler ultrasound or angio-scanner and magnetic reso-
nance angiography of the neck vessels [43]. When the his-
tory is typical with numerous periods, attacks and no
interictal abnormalities on neurological examination,
MRI is not mandatory. Imaging studies in CH patients are
most of the time normal, but lesions can be detected in
secondary cases. An association with pituitary tumors has
been suspected [44]. Any refractory case should undergo
MRI study to exclude a treatable cause. The pituitary,
orbit, and trigeminal pathway have to be specifically
examined with computed tomography (CT) and MRI.
Differential diagnosis
Primary headache diseases
Migraine
The only way to differentiate CH from migraine is the
clinical history. The questionnaire is of paramount impor-
tance. The global picture must be taken into account. In
case of doubt, further observation of attacks by the patient
is warranted. Migraine and CH are both very incapacitat-
ing and share common features, but they also differ on
specific points. Migraine is much more frequent than CH
(15% of the general population versus 0.05%–0.1%),
affects mainly women, and starts earlier in life, often dur-
ing adolescence or around menarche. Migraine attacks
occur at regular intervals over months, without long
remission periods, though in some patients seasonal trig-
gers may cause more frequent attacks (allergies, stress).
Migraine attacks last longer (more than four hours and
can go on for more than 24 hours) [2]. Attacks may have
a prodrome with hunger, fatigue, irritability, and start
more progressively. Patients tend to stay quiet and avoid
any movement. The pain may begin unilaterally but dur-
ing the attack it may radiate to the whole head. Many
patients have attacks on alternate sides. Pain is moderate-
to-severe, but is not described as intolerable or excruciat-
ing. The presence of nausea and/or photophobia and pho-
nophobia is a main clinical criterium [2], but it is not
specific for migraine, as CH can also be accompanied by
nausea, photophobia and phonophobia in up to 50% of
patients [2]. Unilateral photo- and phonophobia may be
more specific of CH and trigeminal autonomic cephalal-
gias in general [45]. In up to 30% of patients with
migraine, autonomic signs like lacrimation and nasal con-
gestion are present. Both CH and migraine can be trig-
gered by alcohol, and relieved by triptans, but CH
necessitates parenteral routes of administration. Stress,
foods (like chocolate) and menstrual cycle, are not typical
triggers for CH. Finally, some cases are difficult to diag-
nose and should be referred to a headache specialist. In
some patients, CH and migraine can coexist, and treat-
ment must be chosen accordingly. Table 4 presents a clin-
ical comparison of CH and migraine.
Other trigeminal autonomic cephalalgias (TACs)
Paroxysmal hemicrania (PH) is more frequent in women
(80–90%) and differs from CH by the shorter length and
higher frequency of attacks [46-48]. Absolute response to
an adequate dose of indomethacin (150 mg per day or
more) confirm the diagnosis of PH [2]. A continuum
between paroxysmal hemicrania and CH has been sug-
gested by some authors, due to an overlap in clinical cri-
teria and anecdotal reports of CH patients responding to
indomethacin. Indomethacin treatment in any refractory
case of CH, or cases with frequent and shorter attacks, has
been suggested by Matharu and Goatsby [49].
SUNCT syndrome is a very rare entity [50]. Its prevalence
is estimated around 6,6 per 100,000 [51]. Attacks are very
short and occur up to 300 times a day.
Table 4: Comparison of migraine and cluster headache
Migraine Cluster headache Common characteristics
No periodicity (except with menses) Periodicity (annual and daily) Incapacitating
Alcohol is a trigger 
Attacks > 4 h Attacks < 3 h Triptan effect (spray and subcutaneous)
Female > Male Male > Female
Prostration, quietness Restlessness, agitation Dysautonomic symptoms 
(typical in CH, but may occur in migraine)
Pain moderate to severe Pain is severe
Pain can be bilateral Unilateral
Nausea and photophobia typical Nausea and photophobia can happen but not typical
Dietary and hormonal triggers No dietary trigger except alcohol NB The two types of headache may coexistOrphanet Journal of Rare Diseases 2008, 3:20 http://www.ojrd.com/content/3/1/20
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Hemicrania continua may be confused with chronic clus-
ter headache, and if there is a doubt, a trial with
indomethacin should be made, HC being highly respon-
sive to this drug [52,53]. Table 5 presents the main char-
acteristics of TACs.
Other ICHD-II categories
Trigeminal neuralgia (TN) and CH both involve parox-
ysms of unilateral and severe pain, but specific traits are
found on the questionnaire [2]. TN is more frequent in
women in their fifties or older. Attacks are centered on
maxillary and/or mandibular area, they are more fre-
quent, briefer, electric-like and are triggered by touching
specific zones of the face or buccal cavity. Eating, laugh-
ing, talking, shaving or brushing the teeth may all trigger
the shocks. Patients may loose weight because they avoid
eating. There is no clustering in periods, and mostly the
pain goes on until the treatment starts. TN responds very
well to carbamazepine. Both diseases may occur in the
same patient as cluster-tic (tic standing for tic douloureux,
a French term). Table 6 summarizes the clinical manifes-
tations helping to distinguish TN from CH.
In an elderly patient with exclusively nocturnal attacks,
hypnic headache may be diagnosed, but it is very rare and
pain is usually bilateral, diffuse and without autonomic
signs. Attacks occur exclusively during sleep [54].
In doubt, the clinician may ask the patient to complete a
diary of the attacks, to precise their duration, autonomic
symptoms, triggers, response to treatment, and daily
cyclicity. The importance of history taking in headache
medicine cannot be overemphasized.
Causes of symptomatic CH
Features suggesting a secondary CH are: persistent or
worsening pain, abnormal signs on neurological exami-
nation, and a first period after 50 years old. An underlying
cause has sometimes been found in a patient with typical
CH features [55,56]. Benign intracranial tumors like men-
ingiomas and neurinomas, but also carcinomas and
metastases, have been reported. There seems to be an
overrepresentation of pituitary tumors in CH patients
[44], and a role of prolactin has been suggested in these
cases. Orbital tumors or infections have been reported.
Sinusitis may present with symptoms typical for CH. Arte-
riovenous malformations and aneurysms, if strategically
located, may cause CH symptoms. In a first episode,
carotid dissection has to be suspected and ruled out (it
also can produce Claude-Bernard-Horner syndrome, and
the pain may respond to triptans) [57]. Any case of refrac-
tory CH deserves a brain MRI. Some experts even recom-
mend MRI for every CH patient, to avoid unnecessary
treatments if a treatable cause is found.
Genetic counseling
As familial cluster headache is rare, thus, considering the
limited knowledge on the genes involved and the trans-
mission mode, genetic counseling is not routinely part of
the CH management. Familial cases should be identified
and, if possible, the family referred to a specialist in cluster
headache. There is no known preventive treatment for
CH, or curative intervention, but affected patients may
inform their families of the CH symptoms, thus any delay
in diagnosis among relatives to be avoided. Antenatal
diagnosis is not applicable
Management
Acute treatments are efficient to alleviate pain during
attacks. Prophylactic treatments aim at reducing the daily
number of attacks. No curative treatment for CH is cur-
rently available. Guidelines (evidence-based recommen-
dations and good practice points) for the treatment of CH
are developed by the European Federation of Neurologi-
cal Societies (EFNS) [58].
Acute management of attacks
Because of the excruciating character of the pain, rapid-
acting treatments are preferred for acute management of
attacks [59]. The oral route of administration is too slow
and is rarely used. Inhaled, subcutaneous and intra-nasal
treatments are preferred. The pain in CH is often underes-
timated by the medical community. Interictally, patients
appear normal. In most cases, witnessing a CH attack is
Table 5: Trigeminal-autonomic cephalalgias (TACs)
Cluster headache Paroxysmal hemicrania SUNCT
Sex ratio M: F 3: 1 1: 2 2: 1
Duration of attacks 15–180 min 2–30 min 5–240 sec
Frequency of attacks 1/2 days to 8/day 5–40/day 3–200/day
Periodicity Episodic form may be seasonal Episodic or chronic Episodic or chronic
Treatment Verapamil Indomethacin Anticonvulsants
Lithium
SteroidsOrphanet Journal of Rare Diseases 2008, 3:20 http://www.ojrd.com/content/3/1/20
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convincing enough, but not possible for every practi-
tioner. Adequate treatments must be provided, and a
nihilistic, observational approach should be absolutely
avoided.
The two most efficient acute treatments are subcutaneous
sumatriptan and high-flow inhaled oxygen.
Sumatriptan is a serotonin 5HT1 B/D agonist, acting on
blood vessels with a vasoconstricting effect, and centrally
on brainstem receptors. Subcutaneous sumatriptan 6 mg
(Imiject, Imitrex) has been shown to efficiently relieve the
CH pain and dramatically improve the management of
patients [60]. After the injection, the patient may feel a
rush of heat and chest tightness that disappear in a few
minutes and are followed by rapid relief of the pain. Intra-
nasal sumatriptan [61,62] and zolmitriptan [63] may be
tried if patients refuse to use injections. Absolute contra-
indications to subcutaneous sumatriptan include preg-
nancy, lactation, coronary artery disease, stroke, and
peripheral artery disease. Relative contra-indications are
age (under 18 or over 65), an isolated controlled vascular
risk factor, Raynaud phenomenon, allergy to sulfa medi-
cations, treatment with a serotonin recapture inhibitor
(SSRI). Maximal doses for 24 h period (sumatriptan 12
mg subcutaneous or 40 mg intra-nasal, zolmitriptan 10
mg intra-nasal) have to be explained to the patient to
avoid dangerous side effects, such as coronary or distal
artery spasm. Surprisingly, CH patients do not develop
medication-overuse headache (MOH) with triptans as
often as migrainers do [64]. They may use regular
sumatriptan for many months without developing a dif-
ferent type of headache. As MOH is more frequent in CH
patients with a history/diagnosis of migraine, these
patients must be carefully monitored for MOH, especially
if CH is chronic and refractory [65].
Inhaled oxygen with high-flow (10 to 15 l per minute)
100% normobaric oxygen breathed through a mask is effi-
cient and useful especially when contra-indications to
triptans exist [66,67]. The device is not easy to carry
around, and not always reimbursed by health security
services, depending on the country. The efficacy of oxygen
has been recently re-examined and confirmed. There are
no contra-indications or limitations for the use of oxygen.
Ergotamine and dihydroergotamine have been used in
CH [68]. They must not be combined with triptans on the
same 24 hour period, have the same contra-indications as
triptans (without additional efficacy), therefore are rarely
useful.
Intra-nasal application of topical lidocaine may be tried in
refractory CH cases or in case of contra-indications to
triptans. Its efficacy is not well proven.
Topic cocaine was used in the past, but abandoned
because of equivocal efficacy, side-effects and risks of
dependency.
Prophylactic treatment
The aim of prophylactic treatment is to reduce the fre-
quency of attacks during the bout. Continuous use of pro-
phylactic treatments in episodic CH is not recommended,
since there is no proof that it prevents the next bout.
Therefore, the dose may be progressively decreased after
two or three months, or after the usual known duration of
the bout. The prophylactic treatment should be restarted
if attacks reappear. In patients with few attacks per week
responding to acute treatment, prophylactic treatment can
be withheld. In chronic CH, treatments are used for a long
term epriod, and a low attack rate has to be reached
(always considering the potentially serious and incapaci-
tating side effects).
The calcium-channel blocker verapamil remains the main
treatment of episodic and chronic CH [69,70]. Doses
range from 360 mg to 960 mg per day, and the maximal
tolerated dose should be reached before concluding about
efficacy. Side effects are weakness, fatigue, lower extremi-
Table 6: Comparison of cluster headache and trigeminal neuralgia
Cluster headache Trigeminal neuralgia
Age Starts around 20–30 60
Sex Male Female
Pain localization Orbital, temporal Nasal, maxillary, dental
Attack duration 15 to 180 minutes Seconds, but repeated shocks
Pain character Knife-like, stabbing, lancinating Electric shocks, burning, stinging
Trigger zone No Yes
Neurovegetative signs Yes No
Refractory period after attack Not typical Yes
Frequency per day 1–8 Highly variable but may be dozens or moreOrphanet Journal of Rare Diseases 2008, 3:20 http://www.ojrd.com/content/3/1/20
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ties edema, and conduction heart block. An electrocardio-
gram should be performed at the baseline and for every
increase in the dose when it exceeds 480 mg per day [71].
Greater occipital nerve blocks are used, based on the con-
nection between this nerve and the trigeminal circuitry
[72]. One randomized study showed that this technique
may end a bout, or, at least, may diminish the number of
attacks per day [73]. More evidence is needed to recom-
mend this procedure [74], but it is widely used by experts
[75,76]. The block is performed with a long-acting inject-
able steroid, sometimes combined with a local anesthetic.
Different combinations have been described. The needle
is inserted midway between the mastoid and the occipital
protuberance, until it touches the occipital bone (sub
occipital technique).
Topiramate has shown a convincing efficacy in CH
[77,78]. Usual dosing is 100 mg per day (range 25 mg to
200 mg). Side effects include numbness and tingling in
the extremities, weight loss, and neuro-cognitive difficul-
ties, all reversible after drug discontinuation.
Lithium is used in chronic CH [69,79,80]. Doses range
from 600 to 1200 mg per day. Blood levels must not
exceed 0,9 mEq per liter, and thyroid and renal function
must be monitored. Side effects include tremors, insom-
nia, fatigue, nausea and blurred vision. Intoxication may
be severe and has to be suspected quickly if nausea, con-
fusion, rigidity and difficulty to walk appear. Because of
these side effects, lithium is used sparingly, in selected
cases only.
A short course of decreasing-dose prednisone (starting at
1 mg/kg) may be used to treat a bout refractory to vera-
pamil (however, recurrence is frequent with the decrease
of the dose). Long-term side effects of corticotherapy
restrict the use of prednisone in chronic CH.
Methysergide acts on serotonin receptors. Doses range
from 6 to 12 mg per day. Some patients do respond very
well to this drug but a major limitation is that triptans and
ergots cannot be used simultaneously because of the risk
of serotoninergic syndrome. The main side effect is nau-
sea, sometimes severe. Methysergide can be considered if
oxygen alone is used as an acute treatment. The main
complication is retroperitoneal, pulmonary or cardiac
fibrosis after prolonged use. This mandates one-month
drug-holiday after six months of use, then methysergide
can be started again. Methysergide is not available in
United States.
Valproic acid [81], pizotifen, gabapentin [82,83],
baclofen [84], and melatonin [85,86] have shown some
effect in CH prophylaxis and may be used in selected
patients as a second-line therapy.
Surgical approaches
Destructive approaches like trigeminal section, thermoco-
agulation of gasserian ganglion, glycerol rhizotomy
[87,88] and radiosurgery [89-92] of the trigeminal nerve
have shown variable results and irreversible complica-
tions like anesthesia dolorosa.
Hypothalamic deep-brain stimulation (hDBS) has shown
a convincing benefit in some refractory patients in series
totalizing a few dozens of cases [93-96], but can be com-
pletely inefficient[97], and has potential serious compli-
cations. Its mechanism is not well understood[98] and no
controlled studies are available.
Neurostimulation of the greater occipital nerve has
recently been described [76,99-101]. It is less invasive
than DBS but costly; its long-term effects are unknown.
Non-pharmacological approaches like massotherapy,
physiotherapy and acupuncture have not been adequately
studied in CH.
Prognosis
CH has a very unpredictable course. Some patients have
only one period of attacks, while in others the disease
evolves from episodic to chronic form. There are no
known factors for chronicization of the CH. Total remis-
sion of the disease has been described. With aging, attacks
often decrease and active CH is rarely seen after age of 75
years.
Conclusion
CH is a primary trigeminal-autonomic cephalalgia
responsible for recurrent unilateral short-lasting attacks of
excruciating orbitotemporal pain. The cause of cluster
headache is not known and there is no unifying hypo-
thesis to explain all the clinical particularities of this dis-
ease. About 10% of CH patients have a familial form and
the existence of genetic factors has been confirmed. The
hypocretin receptor gene may be involved, but implica-
tion of other genes can't be excluded. In the absence of
any radiological or biological marker, diagnosis relies
upon clinical history. Patients are often misdiagnosed as
having secondary headaches due to sinus, dental or eye
disorders or as having migraine, leading to inadequate
management. No curative treatment currently exists, how-
ever efficient treatment do exist to shorten painful attacks
(acute treatments) and to reduce the number of daily
attacks (prophylactic treatments). Ongoing research is
very active. Deep-brain stimulation and occipital nerve
stimulators are promising options for refractory patients
but are used currently in an experimental setting. The cur-Orphanet Journal of Rare Diseases 2008, 3:20 http://www.ojrd.com/content/3/1/20
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rent pathophysiological focus is on the hypothalamus.
The combination of imaging techniques and genetic stud-
ies may help us to better understand this terrible and fas-
cinating condition, ultimately leading to improvement of
the care and quality of life of these patients.
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